Humacyte, Inc.
HUMAWNasdaq
$0.01
↓ -2.1%Jul 17 close · end-of-day
Price
1Y↓ -98.2%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$1.8M
Enterprise Value
-$10.8M
P/E
—
P/S
0.9
P/B
0.2
EV/EBITDA
—
PEG
—
FCF Yield
-5624.5%
Dividend Yield
—
Revenue (TTM)
$2.0M
Net Income (TTM)
-$97.6M
Free Cash Flow (TTM)
-$102.4M
Gross Margin
—
Operating Margin
-5649.2%
Net Margin
-4840.8%
ROE
-839.6%
ROIC
—
Debt / Equity
3.1
Net Cash
$12.7M
Return 1Y
-98.0%
Company profile
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues. Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company was founded in 2004 and is headquartered in Durham, North Carolina.
- CEO
- Laura E. Niklason
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 150
- Headquarters
- North Carolina
- Website
- humacyte.com
Management & directors
- Parikh Shamik JChief Medical Officer
- Sander Dale A.CFO and Chief Corp. Deve. Off.
- Niklason Laura EPresident, CEO and Director
Roles derived from SEC Form 4 filings.
Earnings
HUMAW Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$495,000.00↓ -4.3%
Diluted EPS-$0.09↓ -132.1%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $2.0M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$64.6M | -$81.2M | -$84.6M | -$100.0M | -$114.4M | -$108.1M |
| Net income | -$66.5M | -$26.5M | -$12.0M | -$110.8M | -$148.7M | -$40.8M |
| Diluted EPS | -$11.54 | -$0.66 | -$0.12 | -$1.07 | -$1.26 | -$0.26 |
| Operating cash flow | -$55.6M | -$81.2M | -$71.1M | -$73.3M | -$98.1M | -$105.0M |
| Free cash flow | -$55.9M | -$81.4M | -$72.2M | -$75.6M | -$99.7M | -$105.9M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -5306.0% |
| Net margin | — | — | — | — | — | -2003.6% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $517,000.00 | $301,000.00 | $753,000.00 | $467,000.00 | $495,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$29.5M | -$30.2M | -$28.1M | -$23.2M | -$29.7M | -$24.4M | -$30.8M | -$28.9M |
| Net income | -$56.7M | -$39.2M | -$20.9M | $39.1M | -$37.7M | -$17.5M | -$24.8M | -$17.6M |
| Diluted EPS | -$0.48 | -$0.33 | -$0.16 | $0.28 | -$0.24 | -$0.11 | -$0.19 | -$0.09 |
| Operating cash flow | -$21.3M | -$22.9M | -$26.6M | -$28.6M | -$26.4M | -$23.9M | -$26.1M | -$25.1M |
| Free cash flow | -$21.5M | -$23.8M | -$26.6M | -$28.8M | -$27.0M | -$24.0M | -$26.2M | -$25.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | -4484.3% | -9876.1% | -3239.0% | -6603.0% | -5845.5% |
| Net margin | — | — | — | 7570.4% | -12511.0% | -2325.4% | -5311.4% | -3559.4% |
Company news
Jul 14, 2026
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-05-19 | Sebelius Kathleen | Buy | 56,818 | $0.88 | $49,999.84 | filing |
| 2026-05-18 | Sander Dale A.· CFO and Chief Corp. Dev. Off | Sale | 45,887 | $0.90 | $41,146.87 | filing |
| 2026-05-18 | Parikh Shamik J· Chief Medical Officer | Sale | 45,887 | $0.90 | $41,146.87 | filing |
| 2026-05-18 | Constantino Michael T. | Buy | 11,000 | $0.89 | $9,839.50 | filing |
| 2025-11-16 | Sander Dale A.· CFO and Chief Corp. Deve. Off. | Award | 311,100 | $0.00 | $0.00 | filing |
| 2025-11-16 | Parikh Shamik J· Chief Medical Officer | Award | 311,100 | $0.00 | $0.00 | filing |
| 2025-08-20 | Dougan Brady W | Sale | 591,685 | $1.58 | $934,862.30 | filing |
| 2025-08-20 | Niklason Laura E· President, CEO and Director | Sale | 591,685 | $1.58 | $934,862.30 | filing |
| 2025-08-19 | Dougan Brady W | Sale | 1,100,000 | $1.63 | $1.8M | filing |
| 2025-08-19 | Niklason Laura E· President, CEO and Director | Sale | 1,100,000 | $1.63 | $1.8M | filing |
| 2025-08-18 | Dougan Brady W | Sale | 549,360 | $1.83 | $1.0M | filing |
| 2025-08-18 | Niklason Laura E· President, CEO and Director | Sale | 549,360 | $1.83 | $1.0M | filing |
Latest 12 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.